RPG Life Sciences Ltd (RPGLIFE)

Healthcare · Pharmaceuticals · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹2,584.05 ↑ 10.54% (1Y)

🎯 Key Takeaways

RPG Life Sciences Ltd is in a mature cash cow phase with stable growth, strong profitability, and consistent shareholder returns. The company has demonstrated resilient financial performance over the past year, supported by robust margins and efficient capital allocation.
Revenue grew 10.6% QoQ to ₹196 in Q1FY27.
⚠️ Heavy reliance on a concentrated product portfolio with limited diversification across therapeutic segments, making it vulnerable to regulatory or dem

Market Cap

₹4,274

P/E Ratio

35.7

P/B Ratio

7.06

ROE

19.8%

ROCE

25.8%

Debt/Equity

0.03

Div Yield

0.93%

Promoter

73.0%

✨ Ask AI About RPGLIFE 📊 Interactive Charts

📖 The Story

RPG Life Sciences Ltd is in a mature cash cow phase with stable growth, strong profitability, and consistent shareholder returns. The company has demonstrated resilient financial performance over the past year, supported by robust margins and efficient capital allocation. It operates with minimal debt and high returns on capital, reflecting a disciplined business model in the specialty pharmaceuticals space.

📰 What's Happening

The most recent development was the 19th Annual General Meeting on July 23, 2026, where the company approved audited standalone and consolidated financial statements for FY 2025-26 and declared a dividend of ₹24 per share (300% on ₹8 face value). It also appointed Dr. Pratit Samdani as an independent director for five years and ratified Kirit Mehta & Co. as cost auditors for FY 2026-27. All resolutions received 100% support from the promoter group via e-voting, underscoring governance continuity and shareholder confidence. No new strategic initiatives or business updates were disclosed during the reporting period.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	182	180	177	196
Operating Profit	34	34	27	37
OPM %	18.6%	19.1%	15.3%	19.1%
Net Profit	37	22	30	31
EPS	₹22.28	₹13.38	₹18.08	₹18.60

The company has shown steady revenue and profit growth over the last four quarters, with revenue hovering around ₹180–196 crore and operating profit expanding from ₹22 crore to ₹37 crore. Operating margins have remained stable between 15.3% and 19.1%, indicating consistent pricing and cost control. Net profit rose from ₹22 crore in December 2025 to ₹37 crore in September 2025 before moderating slightly, while EPS followed a similar trend, reflecting stable earnings quality. This profitability trend aligns with the company’s high ROCE of 25.8% and ROE of 19.8%, suggesting efficient use of capital and resilient core operations.

🔮 Management Outlook & What's Next

There is no forward guidance or explicit outlook provided by management in the available filings. The most recent disclosures focus on historical results and governance updates, with no commentary on future performance, market conditions, or strategic priorities. As such, the company’s near-term trajectory appears to be one of continuation rather than transformation, with decisions being reactive rather than forward-looking in the current reporting window.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2026
Equity Capital	13	13
Reserves	517	592
Borrowings	0	20
Total Liabilities	658	793
Fixed Assets	161	200
Investments	127	85
Total Assets	658	793

The balance sheet shows a strong equity base of ₹13 crore supported by substantial reserves of ₹592 crore as of March 2026, up from ₹517 crore a year earlier. Borrowings remain negligible at ₹20 crore, down from zero in the prior year, indicating minimal reliance on debt financing. Total assets grew to ₹793 crore from ₹658 crore, reflecting operational expansion or asset accumulation. The capital structure remains conservative, with a debt-to-equity ratio of 0.03, supporting financial flexibility and low interest burden.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2026
Operating	+57
Investing	+86
Financing	-21
Net Cash Flow	+122

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	73.0%	73.0%	73.0%	73.0%
FII	1.1%	1.0%	0.9%	0.9%
DII	6.7%	7.0%	7.5%	8.7%
Public	15.4%	15.2%	15.0%	13.9%
# Shareholders	26,657	25,905	25,282	23,886

Promoter holding remains stable at 72.95% over the last four quarters, suggesting long-term commitment and confidence in the business. Institutional ownership (FII and DII) has shown a slight upward trend, with FII increasing from 0.87% to 0.95% and DII rising from 7.04% to 8.67% in Q1FY27, indicating growing institutional interest. The number of public shareholders has gradually increased, reflecting broadening retail participation. No pledging or significant dilution events are evident in the data.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.63 L Cr	38.3	18.7%	14.6%	0.05
DIVISLAB	2.43 L Cr	83.2	23.0%	17.4%	0.00
TORNTPHARM	1.89 L Cr	79.1	15.1%	25.7%	1.76
ZYDUSLIFE	1.16 L Cr	25.9	16.8%	16.6%	0.43
CIPLA	1.15 L Cr	34.0	13.2%	9.8%	0.01
LAURUSLABS	1.00 L Cr	91.8	20.8%	20.6%	0.45
LUPIN	98,305	17.4	27.9%	24.7%	0.26
DRREDDY	97,741	30.3	10.1%	8.4%	0.17
MANKIND	97,467	47.7	13.9%	12.7%	0.38
AUROPHARMA	96,836	26.3	12.8%	9.8%	0.20

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. Heavy reliance on a concentrated product portfolio with limited diversification across therapeutic segments, making it vulnerable to regulatory or demand shifts in key markets. 2. Low institutional ownership (FII at 0.95%, DII at 8.67%) may result in limited liquidity and increased volatility. 3. No visible growth strategy or new product pipeline disclosed, raising concerns about long-term revenue sustainability beyond current cash cow dynamics. 4. High promoter ownership (72.95%) could amplify governance risks if not balanced by independent oversight.

📋 Recent Filings

🧠 Analyst's Read

RPG Life Sciences operates as a stable, profitable specialty pharma with strong shareholder returns and a conservative balance sheet, but lacks visible catalysts for growth. Investors should monitor for any strategic shifts, new product launches, or international expansion plans in upcoming filings to assess whether the company is transitioning beyond its current mature phase.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on RPGLIFE

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when RPGLIFE files new disclosures

Track RPGLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RPGLIFE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd